JAMA Oncology’s Post

Tons of new data has come out last year, and is coming out on MRD and GI cancers in 2024. Be sure to take the opportunity to see how you can take advantage of the test to reformulate your plans with your future trials. It will be well worth your time, so add it to your calendar today! #colorectalcancerawareness #colorectalcancer #Signatera #clinicaltrials #clinicalresearch #precisionmedicine #precisiononcology #GEJ Agenus

Immune-reactive cluster (Cl-6) identified by gene-expression profiling may discriminate patients who will have a benefit from immunotherapy in rec/met head and neck squamous cel cancers. In multivariate analysis, Cl-6 survived as prognostic factor for OS and PFS over other clinical and biomolecular factors. May we start also in HNSCC to tell a tailored-treatment approach story?

With the global burden of oral cancer on a steady rise and India contributing to one third of the total cases, it has become all the more important to diagnose these cases earlier, to improve their survival outcomes. In this prospective study of ours, we try to bring forward the various factors that are seen to be associated with a possible delayed diagnosis of oral malignancies. This may help us understand better as to how better to plan screening programs for oral cancers and how to ensure maximum possible reach.

H. pylori is a gram-negative,microaerophilic,spiral (helical) bacterium usually found in the stomach. It is very common, many people have it. H.pylori infec-tion usually has no symptoms but sometimes causes gastritis (stomach inflammation) or ulcers of the stomach or first part of the small intestine. The infec-tion is also associated with the development of cer-tain cancers. Testing is recommended if peptic ulcer disease or low-grade gastric MALT lymphoma (MALToma) is present, after endoscopic resection of early gastric cancer, for first degree relatives with gastric cancer, and in certain cases of dyspepsia. #Hpylori #Hpyloritest #GastrointestinalInfectious #IVD

H. pylori is a gram-negative,microaerophilic,spiral (helical) bacterium usually found in the stomach. It is very common, many people have it. H.pylori infec-tion usually has no symptoms but sometimes causes gastritis (stomach inflammation) or ulcers of the stomach or first part of the small intestine. The infec-tion is also associated with the development of cer-tain cancers. Testing is recommended if peptic ulcer disease or low-grade gastric MALT lymphoma (MALToma) is present, after endoscopic resection of early gastric cancer, for first degree relatives with gastric cancer, and in certain cases of dyspepsia. #Hpylori #Hpyloritest #GastrointestinalInfectious #IVD

🎓Test Yourself & learn! This interactive patient case study will guide you in choosing appropriate treatments for patients with colorectal cancer (#CRC). Make the best decisions for your patients for the best long-term response, and be confident you are choosing the most effective treatment. Top experts Gerald Prager & Joleen Hubbard support you through the case study, providing the latest data and updating you on what 3rd-line treatments are available. Key takeaways: 👉Treatment of advanced CRC should be considered as a continuum of care, and patients should be offered as many life-prolonging therapies as possible 👉Decision-making should consider patients' suitability and tolerability, tumour biomarkers and prior exposure to chemotherapies and/or targeted agents Do you know the latest 3rd and 4th line treatment options for your CRC patients? If you wish to gain CME credits, you can take the accredited e-learning linked below the video. 👉https://ow.ly/TsBq50PTzRE Endorsed by Digestive Cancers Europe #MedEd

Join our discussion with Adham Jurdi and John Simmons on the latest data from ASCO GI including 2024 publications validating the prognostic and predictive capabilities of ctDNA in colorectal, gastroesophageal and pancreatic cancers. Register here: https://ow.ly/i4VE50QW3uk #ASCO #GI24

With ctDNA changing the paradigm of how we view, stage and treat GI cancers, we need a whole new playbook on how to design a successful, efficient clinical trial incorporating #ctDNA. Join us tomorrow at 1pm EST as John Simmons and I break down the latest #signatera data in the context of novel trial designs.

In this feature by iFast TV, I had the pleasure of conducting this full interview in mandarin with Physician He Yuying, Ph.D Gastroenterology, Nanjing University of Chinese Medicine on Managing Long Term Expense Post Cancer and TCM (Traditional Chinese Medicine) Approach in Treatment and Prevention of Colon Cancer. In this feature, I am also sharing as a cancer survivor and financial adviser on long term expense post cancer and implications on financial planning. Colorectal Cancer is the top cancer affecting men and second most common cancer affecting women right now in Singapore. In this interview, we get to learn how important and significant is colorectal health to our overall immunity as well as prevention, management of colorectal cancer during and post treatment. We will also be exploring the implications and strategies used in financial planning for funding treatments as well as for post cancer management with my sharing on post cancer treatment journey and the real cost of cancer. Cancer treatment is not a one-off expense as most people thought. Along with radiotherapy and chemotherapy there are collateral damages to the body. Managing them is important for long term maintenance of good health. https://lnkd.in/gwf9ebX3

HEPATORCH, an international Phase 3 study of toripalimab plus bevacizumab for the first-line treatment of advanced hepatocellular carcinoma (HCC), has successfully met its 2 primary endpoints— progression-free survival (PFS) and overall survival (OS)! Liver cancer is a major health challenge worldwide, and China in particular suffers greatly, with 368,000 new cases and 317,000 deaths in 2022, accounting for more than 40% of all global cases that year. HEPATORCH’s latest results offer new hope for patients, and this marks a significant step forward in the fight against liver cancer. Learn more: https://lnkd.in/enamu5qb #livercancer #hepatocellularcarcinoma #toripalimab #cancertreatment #medicalbreakthrough #clinicalresearch #healthcareinnovation #immunotherapy #hepatorch #junshi #topalliance